Form 8-K - Current report:
SEC Accession No. 0001213900-24-076144
Filing Date
2024-09-05
Accepted
2024-09-05 16:59:33
Documents
13
Period of Report
2024-09-05
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ea021370601-8k_cadrenal.htm   iXBRL 8-K 25975
  Complete submission text file 0001213900-24-076144.txt   200687

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cvkd-20240905.xsd EX-101.SCH 3015
3 XBRL LABEL FILE cvkd-20240905_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE cvkd-20240905_pre.xml EX-101.PRE 22359
15 EXTRACTED XBRL INSTANCE DOCUMENT ea021370601-8k_cadrenal_htm.xml XML 3801
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 241282029
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)